{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:30:51Z","timestamp":1782372651278,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11060-023-04347-x","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T14:01:48Z","timestamp":1688479308000},"page":"565-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas"],"prefix":"10.1007","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9096-8685","authenticated-orcid":false,"given":"Bahattin","family":"Tanr\u0131kulu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8295-6713","authenticated-orcid":false,"given":"Ahmet Harun","family":"Ya\u015far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1528-1744","authenticated-orcid":false,"given":"Cengiz","family":"Canpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3514-084X","authenticated-orcid":false,"given":"Funda","family":"\u00c7orap\u00e7\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-1073","authenticated-orcid":false,"given":"Evrim","family":"Tezcanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-8616","authenticated-orcid":false,"given":"Ufuk","family":"Abacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8015-9916","authenticated-orcid":false,"given":"Ay\u00e7a Er\u015fen","family":"Danyeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-7166","authenticated-orcid":false,"given":"M. Memet","family":"\u00d6zek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"4347_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"4347_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"4347_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/bpa.12336","volume":"26","author":"DA Solomon","year":"2016","unstructured":"Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A (2016) Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26:569\u2013580. https:\/\/doi.org\/10.1111\/bpa.12336","journal-title":"Brain Pathol"},{"key":"4347_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197193","author":"MS Graham","year":"2020","unstructured":"Graham MS, Mellinghoff IK (2020) Histone-mutant glioma: molecular mechanisms, preclinical models, and implications for therapy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21197193","journal-title":"Int J Mol Sci"},{"key":"4347_CR5","first-page":"4607","volume":"11","author":"R Borsuk","year":"2021","unstructured":"Borsuk R, Zhou L, Chang WI, Zhang Y, Sharma A, Prabhu VV, Tapinos N, Lulla RR, El-Deiry WS (2021) Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. Am J Cancer Res 11:4607\u20134623","journal-title":"Am J Cancer Res"},{"key":"4347_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3171\/2019.2.PEDS18480","volume":"23","author":"MD Hall","year":"2019","unstructured":"Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP (2019) First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr 23:719\u2013725. https:\/\/doi.org\/10.3171\/2019.2.PEDS18480","journal-title":"J Neurosurg Pediatr"},{"key":"4347_CR7","unstructured":"University of California SF, Foundation TC-TDD, Foundation MP, Fund StH (2021) Disorders NIoN, Stroke Combination Therapy for the Treatment of Diffuse Midline Gliomas. https:\/\/ClinicalTrials.gov\/show\/NCT05009992"},{"key":"4347_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092064","author":"V Di Ruscio","year":"2022","unstructured":"Di Ruscio V, Del Baldo G, Fabozzi F, Vinci M, Cacchione A, de Billy E, Megaro G, Carai A, Mastronuzzi A (2022) Pediatric diffuse midline gliomas: an unfinished puzzle. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics12092064","journal-title":"Diagnostics (Basel)"},{"key":"4347_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/neuonc\/noq191","volume":"13","author":"KJ Cohen","year":"2011","unstructured":"Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the children\u2019s oncology group. Neuro Oncol 13:317\u2013323. https:\/\/doi.org\/10.1093\/neuonc\/noq191","journal-title":"Neuro Oncol"},{"key":"4347_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/now101","volume":"19","author":"C Jones","year":"2017","unstructured":"Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA (2017) Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol 19:153\u2013161. https:\/\/doi.org\/10.1093\/neuonc\/now101","journal-title":"Neuro Oncol"},{"key":"4347_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00381-016-3153-8","volume":"32","author":"Z Gokce-Samar","year":"2016","unstructured":"Gokce-Samar Z, Beuriat PA, Faure-Conter C, Carrie C, Chabaud S, Claude L, Di Rocco F, Mottolese C, Szathmari A, Chabert C, Frappaz D (2016) Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas. Childs Nerv Syst 32:1415\u20131423. https:\/\/doi.org\/10.1007\/s00381-016-3153-8","journal-title":"Childs Nerv Syst"},{"key":"4347_CR12","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.2174\/0929867327666200806110206","volume":"28","author":"MG Perrone","year":"2021","unstructured":"Perrone MG, Ruggiero A, Centonze A, Carrieri A, Ferorelli S, Scilimati A (2021) Diffuse intrinsic pontine glioma (DIPG): breakthrough and clinical perspective. Curr Med Chem 28:3287\u20133317. https:\/\/doi.org\/10.2174\/0929867327666200806110206","journal-title":"Curr Med Chem"},{"key":"4347_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan MI, Eisenstat DD (2015) DIPG in Children - what can we learn from the past? Front Oncol 5:237. https:\/\/doi.org\/10.3389\/fonc.2015.00237","journal-title":"Front Oncol"},{"key":"4347_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/neuonc\/nox210","volume":"20","author":"SP Caragher","year":"2018","unstructured":"Caragher SP, Hall RR, Ahsan R, Ahmed AU (2018) Monoamines in glioblastoma: complex biology with therapeutic potential. Neuro Oncol 20:1014\u20131025. https:\/\/doi.org\/10.1093\/neuonc\/nox210","journal-title":"Neuro Oncol"},{"key":"4347_CR15","doi-asserted-by":"publisher","first-page":"vi19","DOI":"10.1093\/neuonc\/noy148.067","volume":"20","author":"A Chi","year":"2018","unstructured":"Chi A, Arrillaga-Romany I, Gardner S, Wen P, Batchelor T, Hall M, Odia Y, Khatua S, Zaky W, McGovern S, Harrison R, de Groot J, Sumrall A, Shonka N, Khatib Z, Karajannis M, Mueller S, Tarapore R, Merdinger K, Schalop L, Allen J, Oster W, Mehta P (2018) ACTR-34. Integrated clinical experience with ONC201 in previously-treated H3 K27m-mutant glioma patients. Neurooncology 20:vi19\u2013vi19. https:\/\/doi.org\/10.1093\/neuonc\/noy148.067","journal-title":"Neurooncology"},{"key":"4347_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","volume":"145","author":"AS Chi","year":"2019","unstructured":"Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP (2019) Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 145:97\u2013105. https:\/\/doi.org\/10.1007\/s11060-019-03271-3","journal-title":"J Neurooncol"},{"key":"4347_CR17","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-18-1040","volume":"24","author":"CT Ishida","year":"2018","unstructured":"Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TTT, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD (2018) Metabolic reprogramming by dual AKT\/ERK inhibition through Imipridones elicits unique vulnerabilities in glioblastoma. Clin Cancer Res 24:5392\u20135406. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1040","journal-title":"Clin Cancer Res"},{"key":"4347_CR18","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2016-lb-209","author":"NS Madhukar","year":"2016","unstructured":"Madhukar NS, Elemento O, Benes CH, Garnett MJ, Stein M, Bertino JR, Kaufman HL, Arrillaga-Romany I, Batchelor TT, Schalop L, Oster W, Stogniew M, Andreeff M, El-Deiry WS, Allen JE (2016) Abstract LB-209: D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.Am2016-lb-209","journal-title":"Cancer Res"},{"key":"4347_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(23)00070-0","volume":"24","author":"N Andre","year":"2023","unstructured":"Andre N, Buyens G, Bouffet E, Walker D, Dun MD (2023) Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga? Lancet Oncol 24:209\u2013212. https:\/\/doi.org\/10.1016\/S1470-2045(23)00070-0","journal-title":"Lancet Oncol"},{"key":"4347_CR20","doi-asserted-by":"publisher","first-page":"vdab169","DOI":"10.1093\/noajnl\/vdab169","volume":"3","author":"RJ Duchatel","year":"2021","unstructured":"Duchatel RJ, Mannan A, Woldu AS, Hawtrey T, Hindley PA, Douglas AM, Jackson ER, Findlay IJ, Germon ZP, Staudt D, Kearney PS, Smith ND, Hindley KE, Cain JE, Andre N, La Madrid AM, Nixon B, De Iuliis GN, Nazarian J, Irish K, Alvaro F, Eisenstat DD, Beck A, Vitanza NA, Mueller S, Morris JC, Dun MD (2021) Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma. Neurooncol Adv 3:vdab169. https:\/\/doi.org\/10.1093\/noajnl\/vdab169","journal-title":"Neurooncol Adv"},{"key":"4347_CR21","unstructured":"ClinicalTrials.govNCT03791398 (2018) BrUOG 379 phase Ib\/II trial ONC201 + nivolumab in MSS mCRC (379). https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03791398 term=onc201&draw =2&rank=8&view=results."},{"key":"4347_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/nop\/npv037","volume":"2","author":"SM Chang","year":"2015","unstructured":"Chang SM, Wen PY, Vogelbaum MA, Macdonald DR, van den Bent MJ (2015) Response assessment in neuro-oncology (RANO): more than imaging criteria for malignant glioma. Neurooncol Pract 2:205\u2013209. https:\/\/doi.org\/10.1093\/nop\/npv037","journal-title":"Neurooncol Pract"},{"key":"4347_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12974-022-02630-8","volume":"19","author":"CJ Pachocki","year":"2022","unstructured":"Pachocki CJ, Hol EM (2022) Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. J Neuroinflammation 19:276. https:\/\/doi.org\/10.1186\/s12974-022-02630-8","journal-title":"J Neuroinflammation"},{"key":"4347_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1200\/JCO.2005.04.6599","volume":"24","author":"SS Donaldson","year":"2006","unstructured":"Donaldson SS, Laningham F, Fisher PG (2006) Advances toward an understanding of brainstem gliomas. J Clin Oncol 24:1266\u20131272. https:\/\/doi.org\/10.1200\/JCO.2005.04.6599","journal-title":"J Clin Oncol"},{"key":"4347_CR25","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41467-019-09140-x","volume":"10","author":"AS Harutyunyan","year":"2019","unstructured":"Harutyunyan AS, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N, Deshmukh S, Chen CCL, Belle J, Mikael LG, Marchione DM, Li R, Nikbakht H, Hu B, Cagnone G, Cheung WA, Mohammadnia A, Bechet D, Faury D, McConechy MK, Pathania M, Jain SU, Ellezam B, Weil AG, Montpetit A, Salomoni P, Pastinen T, Lu C, Lewis PW, Garcia BA, Kleinman CL, Jabado N, Majewski J (2019) H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2\/me3 and is essential for glioma tumorigenesis. Nat Commun 10:1262. https:\/\/doi.org\/10.1038\/s41467-019-09140-x","journal-title":"Nat Commun"},{"key":"4347_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.molcel.2019.08.030","volume":"76","author":"S Nagaraja","year":"2019","unstructured":"Nagaraja S, Quezada MA, Gillespie SM, Arzt M, Lennon JJ, Woo PJ, Hovestadt V, Kambhampati M, Filbin MG, Suva ML, Nazarian J, Monje M (2019) Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state. Mol Cell 76:965\u2013980","journal-title":"Mol Cell"},{"key":"4347_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12915-022-01324-0","volume":"20","author":"N Kfoury-Beaumont","year":"2022","unstructured":"Kfoury-Beaumont N, Prakasam R, Pondugula S, Lagas JS, Matkovich S, Gontarz P, Yang L, Yano H, Kim AH, Rubin JB, Kroll KL (2022) The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential. BMC Biol 20:124. https:\/\/doi.org\/10.1186\/s12915-022-01324-0","journal-title":"BMC Biol"},{"key":"4347_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11912-020-0877-0","volume":"22","author":"K Wierzbicki","year":"2020","unstructured":"Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C (2020) Targeting and therapeutic monitoring of H3K27M-mutant glioma. Curr Oncol Rep 22:19. https:\/\/doi.org\/10.1007\/s11912-020-0877-0","journal-title":"Curr Oncol Rep"},{"key":"4347_CR29","doi-asserted-by":"publisher","first-page":"79298","DOI":"10.18632\/oncotarget.17837","volume":"8","author":"I Arrillaga-Romany","year":"2017","unstructured":"Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT (2017) A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 8:79298\u201379304. https:\/\/doi.org\/10.18632\/oncotarget.17837","journal-title":"Oncotarget"},{"key":"4347_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-019-0599-8","volume":"7","author":"MN Stein","year":"2019","unstructured":"Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A (2019) Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer 7:136. https:\/\/doi.org\/10.1186\/s40425-019-0599-8","journal-title":"J Immunother Cancer"},{"key":"4347_CR31","unstructured":"ClinicalTrials.govNCT05542407 (2022) ONC201 and atezolizumab in obesity-driven endometrial cancer. &draw=4&rank=22. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05542407?term=onc201"},{"key":"4347_CR32","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/JCI96711","volume":"128","author":"J Wagner","year":"2018","unstructured":"Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325\u20132338. https:\/\/doi.org\/10.1172\/JCI96711","journal-title":"J Clin Invest"},{"key":"4347_CR33","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-16-2658","volume":"23","author":"MN Stein","year":"2017","unstructured":"Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM (2017) First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 23:4163\u20134169. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2658","journal-title":"Clin Cancer Res"},{"key":"4347_CR34","unstructured":"Chimerix (2023) ONC201 in H3 K27M-mutant diffuse glioma following radiotherapy (the action Study). https:\/\/ClinicalTrials.gov\/show\/NCT05580562"},{"key":"4347_CR35","unstructured":"Chimerix H NIo (2020) Phase I study of oral ONC206 in recurrent and rare primary central nervous system neoplasms. https:\/\/ClinicalTrials.gov\/show\/NCT04541082"},{"key":"4347_CR36","unstructured":"Sabine Mueller M, PhD, Chimerix, Foundation MP, Fund StH, Foundation TCDD, University of California SF (2021) ONC206 for treatment of newly diagnosed, or recurrent diffuse midline gliomas, and other recurrent malignant CNS tumors (PNOC 023). https:\/\/ClinicalTrials.gov\/show\/NCT04732065"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04347-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T14:08:46Z","timestamp":1690898926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04347-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4347"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04347-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"8 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Acibadem University Medical Ethics Committee (Date2 March 2017\/No.2017-4\/2).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in figure(s)  a, b, c, d, e, f, g, h.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}